UM File # 4264

Background
The widespread occurrence of antibiotic resistance among bacteria is causing increasing concern as a major threat to public health threats. Current antibiotics cause death or growth arrest in the target bacteria. As a result, antibiotic use exerts strong selective pressure to favor antibiotic resistant strains. In order to circumvent this serious problem, alternate antimicrobial reagents are needed that suppress the virulence of the pathogens without generating strong selection for antibiotic resistance. Group A Streptococcus (GAS) is an important human pathogen affecting millions of people globally each year. From 5-15% of normal individuals are estimated to harbor this bacterium without sign of disease. GAS is highly specific to its human host and rarely infects other species. Infections caused by GAS include both mild conditions, such as tonsillitis, scarlet fever and impetigo, as well as life threatening diseases, such as toxic-shock-like syndrome and necrotizing fasciitis.

Technology Description
Researchers at University of Michigan have developed methods and compounds that inhibit the pathogenticity of bacteria (e.g., Group A Streptococcus) and the expression or activity of streptokinase from the bacteria. The invention also provides a method of screening for compounds that inhibit the pathogenicity of bacteria compromising a streptokinase gene. The invented compounds can be formulated into medicaments suitable for oral, rectal, nasal, topical, vaginal, parenteral and pulmonary administration.

Applications
• Alternative approach to treat bacterial infection

Advantages
• Reduces selective pressure for resistance

File Number: 4264